The 3D-ASCr scale: A revalidation of the core dimensions of the Altered States of Consciousness Rating Scale 5D(11)-ASC for psychedelic research. [PDF]
J PsychopharmacolStocker K +12 more
europepmc +1 more source
Psychedelic Therapies for Comorbid Major Depressive Disorder and Chronic Pain: A Review of Putative Mechanisms of Action. [PDF]
Pharmacol Res PerspectKazdan J, Ladha KS, Husain MI.
europepmc +1 more source
Mechanistic Basis for 5-HT<sub>2A</sub>R Over 5-HT<sub>2B</sub>R Activation. [PDF]
Nat CommunTang L +7 more
europepmc +1 more source
US Poison Center Encounters for Psilocybin-Related Exposures: 2013-2022. [PDF]
J Am Coll Emerg Physicians OpenMontoy JCC +4 more
europepmc +1 more source
Inhalable Psychedelic 5-MeO-DMT Shows Promise in Treatment-Resistant Depression. [PDF]
J Med ChemAli S +4 more
europepmc +1 more source
The Role of Psychedelics in the Treatment of Substance Use Disorders: An Overview of Systematic Reviews. [PDF]
Brain SciCorrea da Costa S +7 more
europepmc +1 more source
Targeting the 5-HT<sub>2A</sub> Receptor for Developing Psychedelic Drugs and Beyond. [PDF]
J Med ChemAli S, Tian X, Cunningham KA, Zhou J.
europepmc +1 more source
Novel Non-Hallucinogenic Compounds as 5‑HT2A Agonists for Treating Mental Health Disorders, Namely Depression, Anxiety, Stress Disorders, and Eating Disorders. [PDF]
ACS Med Chem LettSabnis RW.
europepmc +1 more source
The structural diversity of psychedelic drug actions revealed. [PDF]
Nat CommunGumpper RH +13 more
europepmc +1 more source
Deconstructing the trip treatment: are hallucinogenic effects critical to the therapeutic benefits of psychedelics? [PDF]
NPP Digit Psychiatry NeurosciGarcia-Romeu A.
europepmc +1 more source